zolgensma
(onasemnogene abeparvovec-xioi)Novartis Gene Therapies, Inc.
Usage: ZOLGENSMA is a gene therapy for treating pediatric patients under 2 years old with spinal muscular atrophy (SMA) due to bi-allelic mutations in the SMN1 gene. Its safety and effectiveness in advanced SMA and for repeat administration have not been evaluated.